Exelixis
Nasdaq EXEL · Alameda, CA
Works in Dermatology · GI & liver · Hematology · Immunology · Metabolic & endocrine · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health
Exelixis is a clinical trial sponsor based in Alameda, CA, listed as Nasdaq EXEL. It has 22 active clinical trials with 14,668 planned participants, across 10 therapeutic areas. Since 2021 it has completed 7 trials and stopped 6 early. Its FDA record on file shows 1 inspection.
Trial track record · since 2021
FDA record
Recent FDA actions
Financials · Nasdaq EXEL
Pipeline · 22 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
2 approved drug applications with a product on the market.
Questions about Exelixis
No warning letter naming Exelixis is on file. FDA has published 1 inspection classification naming it.
FDA has posted 1 inspection classification naming Exelixis. The latest inspection ended on 2026-05-05 and was classified VAI (voluntary action indicated). FDA posts a classification after its review, often months after the inspection ended.
Exelixis is lead sponsor of 22 active clinical trials on ClinicalTrials.gov, with 14,668 planned participants, in Dermatology, GI & liver, Hematology, Immunology and other areas. Since 2021 it has completed 7 trials and stopped 6 early.
Exelixis is based in Alameda, CA and is listed as Nasdaq EXEL. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Exelixis; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-15.
The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.
Approve Suite is not affiliated with Exelixis. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.